Innoviva, Inc. INVA Xerava — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Innoviva, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Innoviva, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Innoviva, Inc.'s xerava — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Innoviva, Inc.'s xerava — revenue?
- Innoviva, Inc. (INVA) reported xerava — revenue of $2.63M in Q1 2026.
- How has Innoviva, Inc.'s xerava — revenue changed year-over-year?
- Innoviva, Inc.'s xerava — revenue decreased by 37.8% year-over-year, from $4.22M to $2.63M.
- What is the long-term trend for Innoviva, Inc.'s xerava — revenue?
- Over 2 years (2023 to 2025), Innoviva, Inc.'s xerava — revenue has grown at a 16.5% compound annual growth rate (CAGR), from $17.32M to $23.52M.
- What does xerava — revenue mean?
- This metric represents the total gross revenue generated from the sale of a specific pharmaceutical product or service, net of any assessed taxes. It serves as a primary indicator of the commercial adoption and market demand for the product within the company's portfolio. Tracking this revenue stream allows investors to evaluate the growth trajectory and financial contribution of the specific asset to the overall business.